Amoéba launches a capital increase of €10 million at €0.30 per share
The Lyon-based greentech company is bringing its existing shareholders into a financing operation designed to support the commercial launch of biocontrol and prepare the monetization of its Willa cosmetic platform.
It presents this market appeal as the final stage of its financing plan before the financial autonomy target set for 2029 onwards.
A fundraising to finance biocontrol and prepare Willa
Amoéba launched on October 2, 2026 the final stage of its financing plan announced on September 24, 2026, in the form of a capital increase with retention of preemptive subscription rights, open to all its shareholders, for an amount of approximately €10 million.
The operation pursues two objectives: financing the commercial launch of the biocontrol business and preparing the monetization of the Willa cosmetic platform. According to the company, the latter is intended to take over the financing until financial autonomy is achieved from 2029 onwards.
Subject to the realization of this monetization, the company indicates that this fundraising should constitute its last market appeal until that horizon.
Terms of the issuance and anchoring of the operation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The issuance covers 32,294,779 new ordinary shares, each accompanied by a share warrant, at the subscription price of €0.30 per share, representing a discount of 23.25% compared to the reference price of €0.3909. Subscription on an irreducible basis is carried out at the rate of 1 new share for 3 existing shares.
The subscription period runs from October 8 to 23, 2026, with preemptive subscription rights being tradable from October 6 to 21, 2026. Marex SA is acting as global coordinator and admission of the new shares to Euronext Growth Paris is scheduled for October 29, 2026.
The company indicates that it has received subscription commitments for a total amount of €7,266,325.20, covering 75% of the envisaged capital increase. The proceeds are intended primarily for commercial development (approximately 30%) and ordinary needs (approximately 70%).
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
